Patent of recombinant human interferon β - 1A of Haizheng pharmaceutical industry was approved

The purification method of recombinant human interferon β - 1A declared by Haizheng pharmaceutical recently has obtained the invention patent certificate of the State Intellectual Property Office It is understood that this drug is the first imitated variety of recombinant human interferon β - 1A in China, while the global scale of recombinant human interferon β - 1A is more than 26 billion yuan International clinical application shows that recombinant human interferon β - 1A is suitable for the treatment of multiple sclerosis, multiple viral infectious diseases and adjuvant treatment of malignant tumors, and it is a high price drug in the world Before that, Avonex company in the United States and Merck xuelanuo company in Germany controlled the whole interferon industry, and the product sales of both companies exceeded 20 billion yuan The recombinant human interferon β - 1A imitated by Haizheng Pharmaceutical Co., Ltd is a class 15 new drug, which has more biological activity than the products on sale in the market and optimizes the industrial process The initial scale of recombinant human interferon β - 1A in Haizheng pharmaceutical industry is close to 40 billion Before other pharmaceutical companies copy recombinant interferon to occupy the market in a large area, Haizheng pharmaceutical is expected to usher in the first opportunity to obtain a market share of at least 1 billion In addition, interferon - β series drugs can also be used to treat Alzheimer's disease At present, the aging of the domestic population is increasingly serious and on the rise, and the clinical Alzheimer's disease is also growing at the same time Interferon β has a significant effect in the treatment of Alzheimer's disease.